FEB 10, 2021 11:10 AM PST

Ketamine Reduces Suicidal Thoughts in Patients with Depression

WRITTEN BY: Annie Lennon

Ketamine has been known for some time for its ability to tackle depression. Now, however, researchers have found that oral doses of the substance can significantly reduce suicidal ideation in patients with chronic suicidal thoughts as well. 

Most studies investigating the potential for ketamine against suicidality have been conducted on intravenous applications. While they show positive results, due to practical limitations of intravenous administration, researchers thought to see whether oral doses could offer benefits too.

As such, the researchers recruited 32 adults aged between 22 and 72, each with major depression and chronic suicidality- ongoing suicidal thoughts that linger in the mind over long periods. Each received 0.5mg of ketamine per kg of body weight, with doses gradually increasing to 3.0mg of ketamine per kg of body weight over a six week period. 

At the end of the six weeks, the researchers noted that 69% of patients went from a high level of suicidal ideation to under the clinical threshold. At a 4-week follow-up after the end of the trial, this figure decreased somewhat to 50% of participants. This means that while orally dosed ketamine seems effective in reducing suicidal thoughts, these positive effects seem to fade over time. The researchers nevertheless noted improvements in secondary measures of depression and suicidality.  

"To the best of our knowledge, the current study is the first to explore the feasibility, safety and tolerability of oral ketamine on chronic suicidality in patients who presented with a range of psychiatric conditions including mood, anxiety, and personality disorders," write the authors of the study.

"Overall, oral ketamine led to significant short-term and prolonged improvements in suicidal ideation, affective symptoms, well-being and socio-occupational functioning in this sample of adults with a history of chronic suicidality and [major depressive disorder]."

 

Sources: Science AlertNature

About the Author
  • Science writer with a keen interest in behavioral biology, consciousness medicine and technology. Her current focus is how the interplay of these fields can create meaningful interactions, products and environments.
You May Also Like
JAN 09, 2021
Drug Discovery & Development
Anticoagulant Drugs Prevent Cancer Spreading to Brain
JAN 09, 2021
Anticoagulant Drugs Prevent Cancer Spreading to Brain
Researchers from the Heidelberg University in Germany have found that anticoagulant drugs that inhibit thrombin (an enzy ...
JAN 18, 2021
Immunology
Arthritis Drug Approved for Critically Ill COVID Patients
JAN 18, 2021
Arthritis Drug Approved for Critically Ill COVID Patients
Critically ill COVID patients in the U.K. may receive an arthritis drug after a study showed that treatment lowered mort ...
MAR 18, 2021
Drug Discovery & Development
New Cancer Immunotherapy Targets Genetic Alteration in All Cancers
MAR 18, 2021
New Cancer Immunotherapy Targets Genetic Alteration in All Cancers
Researchers have developed a prototype for a new kind of cancer immunotherapy. The therapy uses engineered T-cells to ta ...
MAR 30, 2021
Cardiology
Looking at a Fertility Drug's Cardiac Safety
MAR 30, 2021
Looking at a Fertility Drug's Cardiac Safety
New drugs go through a long and arduous process before they can grace a doctor’s office. One of the last steps is ...
APR 04, 2021
Drug Discovery & Development
Ion-Pump for Chemotherapy
APR 04, 2021
Ion-Pump for Chemotherapy
Patients of malignant brain tumors experience recurrences even after subsequent treatments. To address this issue, scien ...
MAY 06, 2021
Drug Discovery & Development
Tweaked Version of Ketamine Could Solve the Opioid Crisis
MAY 06, 2021
Tweaked Version of Ketamine Could Solve the Opioid Crisis
Medications that manage post-operative pain are some of the main entry points to opioid addiction and overdose in the US ...
Loading Comments...